What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Edward C. Keystone spends much of his time researching Rheumatoid arthritis, Internal medicine, Surgery, Rheumatology and Arthritis.
His Rheumatoid arthritis research is multidisciplinary, relying on both Clinical trial, Severity of illness and Rituximab.
His Internal medicine research includes themes of Gastroenterology, Placebo and Placebo-controlled study.
His work deals with themes such as Adverse effect, Infliximab and Immunopathology, which intersect with Surgery.
His Rheumatology study incorporates themes from Concomitant, Tolerability and C-reactive protein.
Edward C. Keystone interconnects Tocilizumab, Pharmacotherapy and Abatacept in the investigation of issues within Arthritis.
His most cited work include:
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis (1603 citations)
- Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. (1589 citations)
- Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks (1376 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Rheumatoid arthritis, Surgery, Methotrexate and Arthritis.
Edward C. Keystone has included themes like Gastroenterology and Placebo in his Internal medicine study.
His research integrates issues of Physical therapy, Adverse effect and Randomized controlled trial in his study of Rheumatoid arthritis.
His study looks at the relationship between Surgery and fields such as Etanercept, as well as how they intersect with chemical problems.
His studies in Methotrexate integrate themes in fields like Tofacitinib, Golimumab, Certolizumab pegol, Connective tissue disease and Combination therapy.
The study incorporates disciplines such as Pharmacotherapy, Severity of illness and Cohort in addition to Arthritis.
He most often published in these fields:
- Internal medicine (72.62%)
- Rheumatoid arthritis (71.76%)
- Surgery (26.80%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (72.62%)
- Rheumatoid arthritis (71.76%)
- In patient (19.88%)
In recent papers he was focusing on the following fields of study:
Edward C. Keystone mostly deals with Internal medicine, Rheumatoid arthritis, In patient, Methotrexate and Adalimumab.
His work on Internal medicine deals in particular with Arthritis, Cohort, Rheumatology, Filgotinib and Disease activity.
His Rheumatology research focuses on Physical therapy and how it connects with Outcomes research.
The concepts of his Rheumatoid arthritis study are interwoven with issues in Randomized controlled trial, Surgery, Placebo and Adverse effect.
His Methotrexate research is multidisciplinary, incorporating elements of Gastroenterology and Golimumab.
His Adalimumab research incorporates elements of Logistic regression, Clinical trial, Biosimilar, Infliximab and Confidence interval.
Between 2015 and 2021, his most popular works were:
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis (328 citations)
- A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy (102 citations)
- Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. (43 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His primary scientific interests are in Internal medicine, Rheumatoid arthritis, Arthritis, Methotrexate and Rheumatology.
In his work, Edward C. Keystone performs multidisciplinary research in Internal medicine and In patient.
His Rheumatoid arthritis study combines topics in areas such as Randomized controlled trial, Surgery, Gastroenterology, Adverse effect and Placebo.
In Placebo, Edward C. Keystone works on issues like Adalimumab, which are connected to Clinical endpoint.
His Arthritis research integrates issues from Visual analogue scale, Autoantibody and Epitope.
While the research belongs to areas of Rheumatology, Edward C. Keystone spends his time largely on the problem of Clinical trial, intersecting his research to questions surrounding Concordance.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
